Home > Publications database > To what extent is male excess risk of advanced colorectal neoplasms explained by known risk factors? Results from a large German screening population. > print |
001 | 169887 | ||
005 | 20240229133659.0 | ||
024 | 7 | _ | |a 10.1002/ijc.33742 |2 doi |
024 | 7 | _ | |a pmid:34278571 |2 pmid |
024 | 7 | _ | |a 0020-7136 |2 ISSN |
024 | 7 | _ | |a 1097-0215 |2 ISSN |
024 | 7 | _ | |a altmetric:109959348 |2 altmetric |
037 | _ | _ | |a DKFZ-2021-01621 |
041 | _ | _ | |a English |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Niedermaier, Tobias |0 P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7 |b 0 |e First author |u dkfz |
245 | _ | _ | |a To what extent is male excess risk of advanced colorectal neoplasms explained by known risk factors? Results from a large German screening population. |
260 | _ | _ | |a Bognor Regis |c 2021 |b Wiley-Liss |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1642168842_11420 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
500 | _ | _ | |a #EA:C070#LA:C070# / 2021 Dec 1;149(11):1877-1886 |
520 | _ | _ | |a Colorectal cancer (CRC) incidence and prevalence of its precursors are substantially higher among males than among females in most countries but the reasons for the male excess risk are incompletely understood. We aimed to assess to what extent it is explained by known risk factors. Prevalence of advanced neoplasia (AN, i.e. CRC or advanced adenoma) and CRC risk and preventive factors were ascertained among 15,985 participants of screening colonoscopy aged 55-79 years in Germany. Logistic regression was used to calculate odds ratios (ORs) for the association between male sex and AN with and without adjustment for known risk and preventive factors. In age-adjusted comparisons, men had twofold increased risk for AN compared to women (OR=1.98, 95% CI 1.79-2.19). After comprehensive adjustment for medical, lifestyle and dietary factors, the OR was reduced to 1.52 (95% CI 1.30-1.77), suggesting that these factors accounted for 47% of male excess risk. Male excess risk increased from proximal colon to distal colon and rectum, with age-adjusted ORs (95% CI) of 1.63 (1.38-1.91), 2.13 (1.85-2.45) and 2.36 (1.95-2.85), respectively, and with the proportion of excess risk explained by covariates being lower for AN in the rectum (26%) than for AN in the proximal (52%) or distal colon (46%). Male excess risk was somewhat lower (age-adjusted OR 1.87) and explained excess risk was smaller (36%) when men were compared to women who never used hormone replacement therapy. In conclusion, most of the male excess risk and the potential to overcome it remain to be explored by further research. This article is protected by copyright. All rights reserved. |
536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
650 | _ | 7 | |a colorectal neoplasia |2 Other |
650 | _ | 7 | |a distal colon |2 Other |
650 | _ | 7 | |a male sex |2 Other |
650 | _ | 7 | |a prevalence |2 Other |
650 | _ | 7 | |a proximal colon |2 Other |
700 | 1 | _ | |a Heisser, Thomas |0 P:(DE-He78)c465139c8b95a919efed7d35ca83ca80 |b 1 |u dkfz |
700 | 1 | _ | |a Gies, Anton |0 P:(DE-He78)6d4d6a0e2d726f899086ca98cd560922 |b 2 |u dkfz |
700 | 1 | _ | |a Guo, Feng |0 P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919 |b 3 |u dkfz |
700 | 1 | _ | |a Amitay, Efrat |0 P:(DE-He78)6e02c183f41e45a5867dec393fb4616a |b 4 |u dkfz |
700 | 1 | _ | |a Hoffmeister, Michael |0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f |b 5 |u dkfz |
700 | 1 | _ | |a Brenner, Hermann |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |b 6 |e Last author |u dkfz |
773 | _ | _ | |a 10.1002/ijc.33742 |g p. ijc.33742 |0 PERI:(DE-600)1474822-8 |n 11 |p 1877-1886 |t International journal of cancer |v 149 |y 2021 |x 1097-0215 |
909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:169887 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)c465139c8b95a919efed7d35ca83ca80 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)6d4d6a0e2d726f899086ca98cd560922 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)6e02c183f41e45a5867dec393fb4616a |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Cancer risk factors and prevention |x 0 |
914 | 1 | _ | |y 2021 |
915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-02-04 |w ger |
915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2021-02-04 |w ger |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-04 |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-02-04 |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b INT J CANCER : 2019 |d 2021-02-04 |
915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b INT J CANCER : 2019 |d 2021-02-04 |
920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
920 | 1 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Präventive Onkologie |x 1 |
920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 2 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)C070-20160331 |
980 | _ | _ | |a I:(DE-He78)C120-20160331 |
980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|